Share on StockTwits

Akorn (NASDAQ:AKRX) will be issuing its Q114 quarterly earnings data on Tuesday, May 6th. Analysts expect the company to announce earnings of $0.15 per share and revenue of $91.44 million for the quarter. Akorn has set its FY14 guidance at $0.76-0.79 EPS.

Akorn (NASDAQ:AKRX) last posted its quarterly earnings results on Monday, March 3rd. The company reported $0.14 earnings per share for the quarter, meeting the analysts’ consensus estimate of $0.14. The company had revenue of $85.00 million for the quarter, compared to the consensus estimate of $83.37 million. During the same quarter last year, the company posted $0.13 earnings per share. Akorn’s revenue was up 18.9% compared to the same quarter last year. On average, analysts expect Akorn to post $0.83 EPS for the current fiscal year and $1.11 EPS for the next fiscal year.

Akorn (NASDAQ:AKRX) traded up 1.66% on Monday, hitting $25.15. The stock had a trading volume of 281,513 shares. Akorn has a 52 week low of $12.86 and a 52 week high of $28.00. The stock has a 50-day moving average of $22.78 and a 200-day moving average of $23.22. The company has a market cap of $2.431 billion and a price-to-earnings ratio of 53.78.

Several analysts have recently commented on the stock. Analysts at Jefferies Group reiterated a “buy” rating on shares of Akorn in a research note on Tuesday, April 29th. They now have a $28.00 price target on the stock. Finally, analysts at Needham & Company LLC raised their price target on shares of Akorn from $25.00 to $28.00 in a research note on Tuesday, March 4th. They now have a “buy” rating on the stock. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Akorn currently has a consensus rating of “Buy” and an average price target of $26.12.

Akorn, Inc is a manufacturer and markets a full line of diagnostic and therapeutic ophthalmic pharmaceuticals as well as niche hospital drugs and injectable pharmaceuticals.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.